| Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant J Lopez Bernal, N Andrews, C Gower, E Gallagher, R Simmons, ... New England Journal of Medicine 385 (7), 585-594, 2021 | 3284 | 2021 |
| Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... New England Journal of Medicine 386 (16), 1532-1546, 2022 | 2195 | 2022 |
| Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative … JL Bernal, N Andrews, C Gower, C Robertson, J Stowe, E Tessier, ... bmj 373, 2021 | 1311 | 2021 |
| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1137 | 2021 |
| Global epidemiology of meningococcal disease LH Harrison, CL Trotter, ME Ramsay Vaccine 27, B51-B63, 2009 | 965 | 2009 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 873 | 2022 |
| Effectiveness of maternal pertussis vaccination in England: an observational study G Amirthalingam, N Andrews, H Campbell, S Ribeiro, E Kara, K Donegan, ... The Lancet 384 (9953), 1521-1528, 2014 | 867 | 2014 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 808 | 2021 |
| Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction CL Trotter, NJ Andrews, EB Kaczmarski, E Miller, ME Ramsay The Lancet 364 (9431), 365-367, 2004 | 752 | 2004 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 732 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 709 | 2021 |
| Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study S de Lusignan, J Dorward, A Correa, N Jones, O Akinyemi, ... The Lancet Infectious Diseases 20 (9), 1034-1042, 2020 | 705 | 2020 |
| Duration of protection against mild and severe disease by Covid-19 vaccines N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... New England Journal of Medicine 386 (4), 340-350, 2022 | 621 | 2022 |
| Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story E Miller, D Salisbury, M Ramsay Vaccine 20, S58-S67, 2001 | 621 | 2001 |
| Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review KF Brown, JS Kroll, MJ Hudson, M Ramsay, J Green, SJ Long, CA Vincent, ... Vaccine 28 (26), 4235-4248, 2010 | 561 | 2010 |
| Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study SN Ladhani, S Collins, A Djennad, CL Sheppard, R Borrow, NK Fry, ... The Lancet Infectious Diseases 18 (4), 441-451, 2018 | 541 | 2018 |
| Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis ME Ramsay, NJ Andrews, CL Trotter, EB Kaczmarski, E Miller Bmj 326 (7385), 365-366, 2003 | 535 | 2003 |
| Immunisation against infectious diseases D Salisbury, M Ramsay, K Noakes The Stationery Office, 2006 | 517* | 2006 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 514 | 2021 |
| Global epidemiology of invasive meningococcal disease RZ Jafri, A Ali, NE Messonnier, C Tevi-Benissan, D Durrheim, J Eskola, ... Population health metrics 11, 1-9, 2013 | 501 | 2013 |
